Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 1/20 | 0.37 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 7/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.36 |
| ▸ | HTR2C | P28335 | 3/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.35 |
| ▸ | EP300 | Q09472 | 1/20 | 0.34 |
| ▸ | FLT3 | P36888 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25965346 | 0.91 | SLC6A2 (0.41) | SLC6A2SLC6A4HTR2CSLC6A3 | |
| SCHEMBL1419786 | 0.88 | ALDH1A1 (0.39) | SLC6A2SLC6A4HTR2CSLC6A3 | |
| SCHEMBL14242799 | 0.86 | ALDH1A1 (0.38) | HTR2C | |
| SCHEMBL1241493 | 0.85 | ALDH1A1 (0.36) | SLC6A2SLC6A4HTR2CSLC6A3 | |
| SCHEMBL7333088 | 0.82 | HTR2C (0.51) | DDB1CRBNSLC6A2SLC6A4HTR2C | |
| SCHEMBL26011715 | 0.80 | NMT1 (0.35) | SLC6A2SLC6A4SLC6A3EP300 | |
| Hydrochloric Acid SCHEMBL9310324 | 0.79 | HTR2C (0.51) | DDB1CRBNSLC6A2SLC6A4HTR2C | |
| SCHEMBL2550898 | 0.79 | DDB1 (0.36) | DDB1CRBNSLC6A2SLC6A4HTR2C | |
| SCHEMBL4010135 | 0.79 | SLC18A3 (0.45) | SLC6A2SLC6A4HTR2CSLC6A3 | |
| Hydrochloric Acid SCHEMBL25354416 | 0.78 | NMT1 (0.34) | SLC6A2SLC6A4HTR2CSLC6A3EP300 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357242-A1 | COMPOUND AS AKT KINASE INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-11-09 | — | — | US | disclosed |
| US-20230357242-A1 | COMPOUND AS AKT KINASE INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-11-09 | — | — | US | disclosed |
| EP-4223754-A1 | COMPOUND AS AKT KINASE INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-08-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357242-A1 | COMPOUND AS AKT KINASE INHIBITOR | AKT2, MTOR, AKT1 | DDB1 4574/4885CRBN 2602/4885SLC6A2 1231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.